Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | ACP3 | P15309 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CASR | P41180 | 6/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5193705 | 0.87 | POLB (0.61) | CYP2D6ACP3POLBCASREPHX2 | |
| SCHEMBL15131229 | 0.87 | POLB (0.61) | CYP2D6ACP3POLBCASREPHX2 | |
| SCHEMBL2341650 | 0.87 | POLB (0.61) | CYP2D6ACP3POLBCASREPHX2 | |
| Hydrochloric Acid SCHEMBL3082165 | 0.86 | CASR (0.60) | CYP2D6ACP3POLBCASREPHX2 | |
| Hydrochloric Acid SCHEMBL31355096 | 0.86 | CASR (0.60) | CYP2D6ACP3POLBCASREPHX2 | |
| Hydrochloric Acid SCHEMBL3067899 | 0.86 | CASR (0.60) | CYP2D6ACP3POLBCASREPHX2 | |
| Hydrochloric Acid SCHEMBL607723 | 0.86 | CASR (0.60) | CYP2D6ACP3POLBCASREPHX2 | |
| SCHEMBL20929726 | 0.85 | HPGDS (0.49) | CYP2D6ACP3CASR | |
| SCHEMBL16548174 | 0.85 | CYP2D6 (0.47) | CYP2D6CASR | |
| SCHEMBL16540044 | 0.85 | CYP2D6 (0.47) | CYP2D6CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101039-A1 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2012-04-26 | — | — | US | disclosed |
| WO-2010136036-A2 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101039-A1 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | CASR, CALCR, PTH1R | CYP2D6 4411/4885ACP3 357/4885POLB 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.